EDLS-302

EDLS-302 is a preclinical-stage therapeutic candidate being developed by Edulis Therapeutics for the treatment of microbiome-related conditions and inflammatory bowel disease. The program utilizes a proprietary endoscopic delivery system featuring a bioresorbable polymer matrix implant, which is designed to be thinner than a grain of rice. This implant provides sustained, localized delivery of a small-molecule medication directly to the gastrointestinal tract for up to 12 months, potentially improving bioavailability and reducing systemic side effects compared to oral administration. While the delivery platform is well-defined, the specific identity and molecular target of the small-molecule active ingredient remain undisclosed.